J.P. Morgan 36th Annual Healthcare Conference

January 8-11, 2018

San Francisco, CA, California

“ENYO Pharma team will be at San Francisco during the J.P. Morgan conference, hosting the largest and most informative healthcare investment symposium in the industry. In 2018, more than 400 companies are expected, both public and private, to deliver presentations to more than 8,000 attendees.” (jpmorgan.com)

https://www.jpmorgan.com/country/US/EN/detail/1320543220127

Read more »

Fierce Biotech – Charles River’s capture compound mass spectrometry enables Enyo Pharma’s target identification

https://www.fiercebiotech.com/cro/charles-river-s-capture-compound-mass-spectrometry-enables-enyo-pharma-s-target-identification

Charles River Laboratories and ENYO Pharma today announced results of a successful collaboration

(http://ir.criver.com/phoenix.zhtml?c=121668&p=irol-newsArticle&ID=2318801)

Read more »

Jefferies 2017 London Healthcare Conference

November 14-15, 2017

London, UK

“Now in its eighth year, the Jefferies Conference is the largest healthcare-dedicated conference in Europe. This year, we hosted 350 participating companies, 1,400 attendees and 3,400 investor and business-to-business meetings. The event featured leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel,

Read more »

ENYO Pharma opens a new subsidiary in Australia as a new managing center for clinical trials

Lyon, October 26, 2017 – ENYO Pharma made a strategic decision and has recently decided to open its first wholly owned subsidiary in Melbourne, Australia, because of its excellent clinical trials development capabilities and attractive conditions offered by the government. The Australian Government is very supportive of biotech startups and the Victorian Government Business Office provides good business development networking. This office will be the new ENYO Pharma center to manage EYP001 (an FXR agonist) clinical trials in the Asia-Pacific region for chronic Hepatitis B.

Read more »